These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8180573)

  • 1. Immune changes in peripheral blood resulting from locally directed interleukin-2 therapy in squamous cell carcinoma of the head and neck.
    Dadian G; Riches PG; Henderson DC; MacLennan K; Lorentzos A; Moore J; Hobbs JR; Gore ME
    Eur J Cancer B Oral Oncol; 1993 Jan; 29B(1):29-34. PubMed ID: 8180573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.
    Gratama JW; Bruin RJ; Lamers CH; Oosterom R; Braakman E; Stoter G; Bolhuis RL
    Clin Exp Immunol; 1993 May; 92(2):185-93. PubMed ID: 8485906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
    Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
    Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
    Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The phenotypic changes in tumour infiltrating lymphocytes and tumour cells following intra-arterial infusion of interleukin-2 in patients with squamous cell carcinoma.
    Salter J; Maclennan KA; Moore J; Dadian G; Riches PG; Gore ME
    J Pathol; 1995 Jun; 176(2):167-73. PubMed ID: 7636627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Production by human squamous cell carcinoma of a factor inducing activation and proliferation of immune cells.
    Hirabayashi H; Yasumura S; Lin WC; Amoscato A; Johnson JT; Herberman RB; Whiteside TL
    Arch Otolaryngol Head Neck Surg; 1995 Mar; 121(3):285-92. PubMed ID: 7873144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD69, CD25, and HLA-DR activation antigen expression on CD3+ lymphocytes and relationship to serum TNF-alpha, IFN-gamma, and sIL-2R levels in aging.
    Rea IM; McNerlan SE; Alexander HD
    Exp Gerontol; 1999 Jan; 34(1):79-93. PubMed ID: 10197730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of blood transfusion during radiotherapy on the immune function of patients with cancer of the uterine cervix: role of interleukin-10.
    Santin AD; Bellone S; Palmieri M; Bossini B; Dunn D; Roman JJ; Pecorelli S; Cannon M; Parham GP
    Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1345-55. PubMed ID: 12459356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.
    Kroesen BJ; Buter J; Sleijfer DT; Janssen RA; van der Graaf WT; The TH; de Leij L; Mulder NH
    Br J Cancer; 1994 Oct; 70(4):652-61. PubMed ID: 7917912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD3/anti-CD28 bead stimulation overcomes CD3 unresponsiveness in patients with head and neck squamous cell carcinoma.
    Shibuya TY; Wei WZ; Zormeier M; Ensley J; Sakr W; Mathog RH; Meleca RJ; Yoo GH; June CH; Levine BL; Lum LG
    Arch Otolaryngol Head Neck Surg; 2000 Apr; 126(4):473-9. PubMed ID: 10772300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunopharmacology and cytokine production of a low-dose schedule of intraperitoneally administered human recombinant interleukin-2 in patients with advanced epithelial ovarian carcinoma.
    Freedman RS; Gibbons JA; Giedlin M; Kudelka AP; Kavanagh JJ; Edwards CL; Carrasco CH; Nash MA; Platsoucas CD
    J Immunother Emphasis Tumor Immunol; 1996 Nov; 19(6):443-51. PubMed ID: 9041464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoral administration of recombinant human interleukin 12 in head and neck squamous cell carcinoma patients elicits a T-helper 1 profile in the locoregional lymph nodes.
    van Herpen CM; Looman M; Zonneveld M; Scharenborg N; de Wilde PC; van de Locht L; Merkx MA; Adema GJ; de Mulder PH
    Clin Cancer Res; 2004 Apr; 10(8):2626-35. PubMed ID: 15102664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
    Santin AD; Ravaggi A; Bellone S; Pecorelli S; Cannon M; Parham GP; Hermonat PL
    Gynecol Oncol; 2001 Jun; 81(3):424-32. PubMed ID: 11371133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
    Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
    J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's Disease (AD) individuals.
    Lombardi VR; García M; Rey L; Cacabelos R
    J Neuroimmunol; 1999 Jun; 97(1-2):163-71. PubMed ID: 10408971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of granulocyte colony-stimulating factor mobilization on phenotypical and functional properties of immune cells.
    Tayebi H; Kuttler F; Saas P; Lienard A; Petracca B; Lapierre V; Ferrand C; Fest T; Cahn J; Blaise D; Kuentz M; Hervé P; Tiberghien P; Robinet E
    Exp Hematol; 2001 Apr; 29(4):458-70. PubMed ID: 11301186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes.
    Hänninen EL; Körfer A; Hadam M; Schneekloth C; Dallmann I; Menzel T; Kirchner H; Poliwoda H; Atzpodien J
    Cancer Res; 1991 Dec; 51(23 Pt 1):6312-6. PubMed ID: 1933892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Covalent linking of proteins and cytokines to suture: enhancing the immune response of head and neck cancer patients.
    Shibuya TY; Kim S; Nguyen K; Parikh P; Wadhwa A; Brockardt C; Do J
    Laryngoscope; 2003 Nov; 113(11):1870-84. PubMed ID: 14603040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating levels of cytokines and soluble cytokine receptors in various T-cell malignancies.
    Raziuddin S; Sheikha A; Abu-Eshy S; al-Janadi M
    Cancer; 1994 May; 73(9):2426-31. PubMed ID: 8168046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human cytotoxic T-cell lines with restricted specificity for squamous cell carcinoma of the head and neck.
    Yasumura S; Hirabayashi H; Schwartz DR; Toso JF; Johnson JT; Herberman RB; Whiteside TL
    Cancer Res; 1993 Mar; 53(6):1461-8. PubMed ID: 8443824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.